Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: The evidence to date

Alzheimer Disease and Associated Disorders

Volumn 20, Issue 1, 2006, Pages 23-29

  Bullock, Roger ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Alzheimer disease; Caregiver burden; Costs; Efficacy; Institutionalization; Memantine; Safety

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RIVASTIGMINE; TACRINE; AMINO ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NOOTROPIC AGENT;

ALZHEIMER DISEASE; CAREGIVER BURDEN; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; CAREGIVER; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE COURSE; DRUG ANTAGONISM; ECONOMICS; FEMALE; INSTITUTIONALIZATION; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INSTITUTIONALIZATION; MALE; MEMANTINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 33745661717     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000201847.29836.a5     Document Type: Review

References (55)

1. Bullock R, Hammond G. Realistic expectations: the management of severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17:S80-S85.
2. Tariot PN. Medical management of advanced dementia. J Am Geriatr Soc. 2003;51:S305-S313.
3. Wancata J, Musalek M, Alexandrowicz R, et al. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry. 2003;18:306-313.
4. Cummings JL, Cole G. Alzheimer disease. JAMA. 2002;287:2335-2338.
5. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122.
6. Fratiglioni L. Epidemiology of Alzheimer's disease. In: Wimo A, Jonsson B, Karlsson G, Winblad B, eds. Health Economics of Dementia. Chichester, UK: John Wiley & Sons Ltd; 1998:13-31.
7. Wimo A, Winblad B, Aguero-Torres H, et al. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 2003;17:63-67.
8. Knopman D, Donohue JA, Gutterman EM. Patterns of care in the early stages of Alzheimer's disease: Impediments to timely diagnosis. J Am Geriatr Soc. 2000;48:300-304.
9. Ferris SH, Steinberg G, Shulman E, et al. Institutionalisation of Alzheimer's disease patients: reducing precipitating factors through family counselling. Home Health Care Serv Q. 1987;8:23-51.
10. Bullock R. The needs of the caregiver in the long-term treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2004;18:S17-S23.
11. Boller F, Verny M, Hugonot-Diener L, et al. Clinical features and assessment of severe dementia. A review. Eur J Neurol. 2002;9:125-136.
12. Hebert M, Parlato V, Lese GB, et al. Survival in institutionalized patients. Influence of dementia and loss of functional capacities. Arch Neurol. 1995;52:469-476.
13. Gauthier S, Bodick N, Erzigkeit E, et al. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11(Suppl 3):6-7.
14. Voisin T, Reynish E, Portet F, et al. What are the treatment options for patients with severe Alzheimer's disease? CNS Drugs. 2004;18:575-583.
15. Bloom BS, de Pouvourville N, Straus WL. Cost of illness of Alzheimer's disease: how useful are current estimates? Gerontologist. 2003;43:158-164.
16. Lowin A, Knapp M, McCrone P. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding. Int J Geriatr Psychiatry. 2001;16:1143-1148.
17. Wimo A, Winblad B. Health economic aspects of Alzheimer's disease and its treatment. Psychogeriatrics. 2001;3:189-193.
18. Livingston G, Katona C, Roch B, et al. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care - the LASER-AD Study. Curr Med Res Opin. 2004;S7:1007-1016.
19. Gonzalez-Salvador MT, Arango C, Lyketsos CG, et al. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry. 1999;14:701-710.
20. Wright LK, Hickey JV, Buckwalter KC, et al. Emotional and physical health of spouse caregivers of persons with Alzheimer's disease and stroke. J Adv Nurs. 1999;30:552-563.
21. Wimo A, Winblad B, Grafstrom M. The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment. Int J Geriatr Psychiatry. 1999;14:338-347.
22. Paton J, Johnston K, Katona C, et al. What causes problems in Alzheimer's disease: attributions by caregivers. A qualitative study. Int J Geriatr Psychiatry. 2004;19:1-6.
23. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137-147.
24. Danysz W, Parsons CG, Quack G. NMDA channel blockers: memantine and amino-aklylcyclohexanes-in vivo characterization. Amino Acids. 2000;19:167-172.
25. Farlow MR. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. Geriatrics. 2004;59:22-27.
26. Mattson MP, Bruce AJ, Mark RJ. Amyloid cytotoxicity and Alzheimer's disease: roles of membrane oxidation and perturbed ion homeostasis. In: Brioni JD, ed. Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations. New York: Wiley-Liss; 1997:239-285.
27. Tariot PN, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord. 2003;17:S105-S113.
28. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613-622.
29. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology. 1999;38:735-767.
30. Emre M. Drugs in development and experimental approaches. In: Qizilbashi SL, Chui H, Tariot P, et al., eds. Evidence-Based Dementia Practice. London: Blackwell; 2002:447-457.
31. Krieglstein J, Lippert K, Poch G. Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology. 1996;35:1737-1742.
32. Li L, Sengupta A, Haque N, et al. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004;566:261-269.
33. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613-620.
34. Aupperle PM, Koumaras B, Chen M, et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin. 2004;20:1605-1612.
35. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
36. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.
37. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135-146.
38. Ferris SH, Schmidt F, Doody R, et al. Long-term treatment with the NMDA antagonist, memantine: results of a 24-week, open-label extension study in advanced Alzheimer's disease [abstract]. Neurology. 2003;60(suppl 1):A414.
39. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry. 2004;19:919-925.
40. Sackett DL, Straus SE, Richardson S, et al. Evidence Based Medicine, 3rd edn. London: Churchill Livingstone; 2005.
41. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. New York: Academic Press; 1985.
42. European Agency for the Evaluation of Medicinal Products. European Public Assessment Report (EPAR) for Memantine (CPMP/1604/02). Available at: www.emea.eu.int/humandocs/Humans/EPAR/axura/axura.htm Accessed 23 July, 2004.
43. Vercelletto M, Delamarre Damier F, Rive B. Effect size estimates in the treatment of moderate to severe Alzheimer's disease with memantine. Poster presented at the International Symposium of the Advances in Alzheimer Therapy 2004; Montreal, Canada.
44. Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry. 2000;15:203-207.
45. Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Can Med Assoc J. 2003;169:557-564.
46. Doody R, Wirth Y, Schmitt F, et al. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;18:227-232.
47. Wimo A, Winblad B, Stoffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics. 2003;21:327-340.
48. Rive B, Vercelletto M, Damier F, et al. Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:1-7.
49. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210-216.
50. Lechowski L, Dieudonne B, Tortrat D, et al. Role of behavioural disturbance in the loss of autonomy for activities of daily in Alzheimer patients. Int J Geriatr Psychiatry. 2003;18:977-982.
51. Cummings J, Tariot P, Graham SM, et al. Effect of memantine on behavioral outcomes in moderate to severe Alzheimer's disease. Neurobiol Aging. 2004;25(Suppl 1).
52. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised controlled trials. Int J Geriatr Psychiatry. 2005;20:459-464.
53. Wenk GL, Quack G, Moebius HJ, et al. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 2000;66:1079-1083.
54. Calabrese P, Essner, Förstl H. The efficacy and tolerability of memantine in AD: a naturalistic study. Poster presented at the 7th International Conference on Alzheimer's and Parkinson's Disease. Sorrento, Italy; March 9-13, 2005.
55. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105-2115.